QUESTIONS LEADING TO A SEARCH FOR ANSWERS

We welcome challenge, and IBD is no exception. It’s estimated that more than half of patients living with IBD are unable to achieve and maintain disease remission, despite currently available therapies.1

scroll

RAPID AND DURABLE CONTROL IS KEY FOR PATIENTS WITH UC

Patients with symptoms of moderate to severe ulcerative colitis (UC) at diagnosis, evidence of deep ulceration on endoscopy, or those experiencing a disease flare within 12 months of steroid treatment have a poor prognosis.2-7

Rapid, durable, and timely control of inflammation improves disease prognosis in patients with moderate to severe UC.8-11 Sustained control of inflammation could potentially lower disease activity, prevent complications, improve quality of life, and maintain steroid-free remission.12,13

Patient meeting doctor for medical prescription
Doctor and nurse reviewing notes

CLEARING A PATH TO REMISSION

HCPs need to find a treatment balance that maintains optimal control of inflammation while minimising unwanted side effects. Steroids can get inflammation under control in the short term but have significant side effects and are not effective for maintenance therapy. Prolonged use of steroids increases disease burden in patients living with IBD.3,14-16

In patients with moderate to severe UC, particularly those with a poor prognosis, earlier treatment with effective, advanced therapies allowing for steroid-free maintenance is recommended.17 Clinical guidelines recommend early introduction of advanced therapies to improve patient outcomes in moderate to severe UC.17,18

Currently, primary non-response to advanced therapies is ~26%, and loss of response after initially responding is ~56%.1,11,19 There is an unmet need for advanced therapies earlier in the disease course that are reliable, well-tolerated, and highly efficacious.